Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Suh Yoon | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Lee, Youn Jae | - |
dc.contributor.author | Park, Sung Jae | - |
dc.contributor.author | Yoo, Ki Young | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.date.available | 2019-03-08T17:01:44Z | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9478 | - |
dc.description.abstract | Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon alpha-2a plus ribavirin for CHC in hemophilia. Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests. Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naive patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis. Conclusions: Peginterferon alpha-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ASSOC STUDY LIVER | - |
dc.title | Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.3350/cmh.2015.21.2.125 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, v.21, no.2, pp 125 - 130 | - |
dc.identifier.kciid | ART002001531 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000409422800004 | - |
dc.identifier.scopusid | 2-s2.0-85050578549 | - |
dc.citation.endPage | 130 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 125 | - |
dc.citation.title | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.citation.volume | 21 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Hemophilia | - |
dc.subject.keywordAuthor | Peginterferon | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.